Stephen Thomas, MD
Internal Medicine · Mesa, AZNPI 1508849985
Payments from drug & device makers
Across 76 payments — averaging $18.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$297
- Abbott$161
- Astellas Pharma US Inc$103
- GSK$100
- Novo Nordisk$95
- Boston Scientific$87
- plus $582 from 18 others
What the payments were for
- Food & beverage$1,424100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 15 | $297 |
| Abbott | 9 | $161 |
| Astellas Pharma US Inc | 5 | $103 |
| GSK | 5 | $100 |
| Novo Nordisk | 5 | $95 |
| Boston Scientific | 4 | $87 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $72 |
| Pfizer | 4 | $69 |
| Dexcom, Inc. | 3 | $67 |
| Lucid Diagnostics Inc. | 1 | $59 |
| Johnson & Johnson | 3 | $55 |
| Novartis | 3 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $37 |
| Ferring Pharmaceuticals Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $18 |
| Teleflex LLC | 1 | $17 |
| AstraZeneca | 1 | $17 |
| Inspire Medical Systems, Inc. | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Saluda Medical Americas, Inc. | 1 | $15 |
| Mylan Specialty L.p. | 1 | $15 |
| Vertos Medical, Inc. | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $12 |
How this compares
$1,424 in reported general payments places this provider in the 80th percentile of 2,212 internal medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 130 | $178,000 |
| JardianceEmpagliflozin | 62 | $102,326 |
| XareltoRivaroxaban | 67 | $72,440 |
| TrulicityDulaglutide | 22 | $47,189 |
| OzempicSemaglutide | 26 | $44,677 |
| JanuviaSitagliptin Phosphate | 21 | $33,085 |
| MounjaroTirzepatide | 19 | $22,694 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $10,021 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 45 | $8,946 |
| Atorvastatin Calcium | 973 | $7,490 |
| Levothyroxine Sodium | 783 | $7,366 |
| Omeprazole | 380 | $4,443 |
| Losartan Potassium | 503 | $3,976 |
| Estradiol | 49 | $3,814 |
| Rosuvastatin Calcium | 349 | $3,729 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $69 | $178,000130 claims |
| Boehringer IngelheimJardiance | $18 | $102,32662 claims |
| Johnson & JohnsonXarelto | $55 | $72,44067 claims |
| Novo NordiskOzempic | $95 | $44,67726 claims |
| GSKBreo Ellipta | $100 | $10,02118 claims |
| AbbVieSynthroid | $297 | $3,56553 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,212 internal medicine providers in Arizona.
Other internal medicine in Mesa
- Yessica SachdevaMesa$13.7M
- Tami BruceMesa$976K
- Ali ImranMesa$240K
- Louise TaberPhoenix$8.5M
- Janelle WeyerChandler$5.5M
- Robert MutterperlTucson$5.3M
- Jalal AbbasSun City West$4.8M
- Nebojsa SkrepnikTucson$4.7M
- Philip MathewTempe$4.1M
- Justin MoserScottsdale$3.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.